^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
Published date:
06/01/2023
Excerpt:
This multicenter phase I trial investigated the safety, tolerability, pharmacokinetics (PK), and efficacy of KN046....In the NSCLC subgroup, all patients were with EGFR mutation. the ORR was 6.3% (95% CI 0.8% to 20.8%), and the median DOR was 17.3 (95% CI 16.6 to NE) months with a 1-year DOR rate of 100.0%. The median PFS was 2.5 (95% CI 1.3 to 2.8) months; the median OS was 7.8 (95% CI 5.3 to 14.8) months with a 1-year OS rate of 41.7% (95% CI 25.6% to 57.0%).
DOI:
10.1136/jitc-2022-006654
Trial ID:
